Form 8-K - Current report:
SEC Accession No. 0001610618-24-000091
Filing Date
2024-07-18
Accepted
2024-07-18 16:31:56
Documents
15
Period of Report
2024-07-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20240718.htm   iXBRL 8-K 58235
2 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION exhibit312024-07x18.htm EX-3.1 10153
3 2024 EQUITY INCENTIVE PLAN exhibit1012024-07x18.htm EX-10.1 332069
  Complete submission text file 0001610618-24-000091.txt   593774

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20240718.xsd EX-101.SCH 1899
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20240718_lab.xml EX-101.LAB 23707
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20240718_pre.xml EX-101.PRE 13583
17 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20240718_htm.xml XML 2929
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 241125127
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)